PDGFB and metabolic dysfunction-associated steatotic liver disease: Collectively, these results identify miR‐31‐5p as a key therapeutic modulator within EVs that attenuates PDGFB signalling from hepatic macrophages, thereby alleviating NAFLD pathology and preserving hippocampal health.